A Randomized, Double-blind, Phase III Study Evaluating Fixed Dose, Once-Per-Cycle Pegylated Filgrastim (SD/01) vs Daily Filgrastim to Support Chemotherapy for Breast Cancer

James Metz, MD
University of Pennsylvania Cancer
Last Modified: May 12, 2001

Presenter: M. Green
Affiliation: Multicenter Trial

Background:
  • It has been shown prolonged neutropenia associated with chemotherapy administration can be significantly decreased by daily Filgrastim. Pegylated Filgrastim is a sustained duration form administered once per chemotherapy cycle. This study was performed to compare the administration of daily Filgrastim vs. once per cycle Pegylated Filgrastim
Materials and Methods:
  • Double-blind randomized study of high risk breast cancer patients, stage II-IV.
  • Chemotherapy consisted of 4 cycles of Doxorubicin and Docetaxel
  • 157 patients were randomized to receive Pegylated Filgrastim at a single fixed dose of 6 mg on day 1 of each cycle of chemotherapy vs. daily Filgrastim.
  • Those patients on the Pegylated Figrastin arm received a placebo injection on all other days of the chemotherapy cycle.
  • Baseline demographics were equally matched between the two groups
Results:
  • The duration of severe neutropenia in cycle 1 was not significantly different at 1.6 vs 1.8 days.
  • There was no difference in the mean duration of neutropenia with any of the chemotherapy cycles between the two groups
  • The fixed dose of Pegylated Filgrastim was adequate for all weights of patients in this study
  • Chemotherapy compliance was > 90% for both groups
  • Cytokine related bone pain was not significantly different at 42% (Figrastim) vs 37% (Pegylated Filgrastim)
  • Overall, adverse events were not significantly different.
Authors' Conclusions
  • A 6 mg dose of Pegylated Filgrastim on day 1 of each chemotherapy cycle is as effective as daily Filgrastin
  • Pegylated Filgrastim and daily Filgrastim are equally tolerated
  • Weight of the patients did not effect the efficacy or toxicity of Pegylated Filgrastim
  • This fixed dose of Pegylated Filgrastim may increase compliance and efficacy of treatment
Clinical/Scientific Implications:

ASCO Abstract 90

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

Blogs

12 Simple Ways to Get Back Into Life With Cancer
by Marlys Johnson
July 19, 2016

Is There Anything I Can Do For You?
by OncoLink Team
August 9, 2016

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Want up to date Cancer Treatment News? Subscribe to our eNewsletter. Subscribe Now